<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2013-01-04" updated="2020-01-02">
  <drugbank-id primary="true">DB08828</drugbank-id>
  <name>Vismodegib</name>
  <description>Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.</description>
  <cas-number>879085-55-9</cas-number>
  <unii>25X868M3DS</unii>
  <average-mass>421.297</average-mass>
  <monoisotopic-mass>420.010218428</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7369</ref-id>
        <pubmed-id>19726763</pubmed-id>
        <citation>Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009  Sep 2.</citation>
      </article>
      <article>
        <ref-id>A7370</ref-id>
        <pubmed-id>23662017</pubmed-id>
        <citation>Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.</indication>
  <pharmacodynamics>Vismodegib selectively binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway. </pharmacodynamics>
  <mechanism-of-action>Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Vismodegib binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway. </mechanism-of-action>
  <toxicity>Increased risk of embryo-fetal death and significant birth defects. Common adverse event include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia. </toxicity>
  <metabolism>The main metabolic enzymes are CYP2C9 and CYP3A4, however more than 98% of total systemic vismodegib is not metabolized. Metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in feces are produced in vitro by recombinant CYP2C9 and CYP3A4/5.</metabolism>
  <absorption>The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food. </absorption>
  <half-life>The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.</half-life>
  <protein-binding>Vismodegib is highly protein bound with plasma protein binding at about 99%. Vismodegib binds to the plasma proteins, albumin and alpha-1-acid glycoprotein (saturable bnding).</protein-binding>
  <route-of-elimination>Vismodegib is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.</route-of-elimination>
  <volume-of-distribution>Vismodegib has a volume of distribution of 16.4 to 26.6 L.</volume-of-distribution>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.</description>
    <direct-parent>Benzanilides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Anilides</subclass>
    <alternative-parent>2-halobenzoic acids and derivatives</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzamides</alternative-parent>
    <alternative-parent>Benzenesulfonyl compounds</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Chlorobenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylpyridines</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Sulfones</alternative-parent>
    <alternative-parent>Vinylogous halides</alternative-parent>
    <substituent>2-halobenzoic acid or derivatives</substituent>
    <substituent>2-phenylpyridine</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzanilide</substituent>
    <substituent>Benzenesulfonyl group</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Halobenzoic acid or derivatives</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Sulfone</substituent>
    <substituent>Sulfonyl</substituent>
    <substituent>Vinylogous halide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english/spanish" coder="inn/usan">Vismodegib</synonym>
    <synonym language="french" coder="inn">Vismod√©gib</synonym>
    <synonym language="latin" coder="inn">Vismodegibum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Erivedge</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA203388</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Erivedge</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02409267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Erivedge</name>
      <ingredients>Vismodegib</ingredients>
    </mixture>
    <mixture>
      <name>Erivedge</name>
      <ingredients>Vismodegib</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Aniline Compounds</category>
      <mesh-id>D000814</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>BCRP/ABCG2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors</category>
      <mesh-id>D065689</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors</category>
      <mesh-id>D065687</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors</category>
      <mesh-id>D065688</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hedgehog Pathway Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Smoothened Receptor Antagonists</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XX43">
      <level code="L01XX">Other antineoplastic agents</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>5l7i</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08828.pdf?1357433662</fda-label>
  <patents>
    <patent>
      <number>9278961</number>
      <country>United States</country>
      <approved>2016-03-08</approved>
      <expires>2028-12-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7888364</number>
      <country>United States</country>
      <approved>2011-02-15</approved>
      <expires>2028-11-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Food does not affect absorption.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfinpyrazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Iproniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The metabolism of Vismodegib can be increased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Torasemide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Dapsone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The metabolism of Diethylstilbestrol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The metabolism of Morphine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The metabolism of Sulfadiazine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The metabolism of Eszopiclone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Rosiglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Cyclophosphamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Zafirlukast can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The metabolism of Piroxicam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The metabolism of Tretinoin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The metabolism of Repaglinide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Almotriptan can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Irbesartan can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Fluvastatin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The metabolism of Tolbutamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Pioglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The metabolism of Ifosfamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Halofantrine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Ketamine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The metabolism of Sitagliptin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The metabolism of Mestranol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Licofelone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The metabolism of Beraprost can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The metabolism of Odanacatib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The metabolism of Olodaterol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The metabolism of Dasabuvir can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Lobeglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The metabolism of Netoglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The metabolism of Rivoglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The metabolism of Ciglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The metabolism of Selexipag can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The metabolism of Balaglitazone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The metabolism of Dexibuprofen can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Capravirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The metabolism of Ketorolac can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Carbamazepine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The metabolism of Paclitaxel can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Phenytoin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The metabolism of Carisoprodol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The metabolism of Methohexital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Thioridazine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Clopidogrel can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The metabolism of Methylphenobarbital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Rabeprazole can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The metabolism of Escitalopram can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The metabolism of Hexobarbital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The metabolism of Barbital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The metabolism of Methsuximide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The metabolism of Dexlansoprazole can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Artemether can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The metabolism of Etizolam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Triclabendazole can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The metabolism of Lynestrenol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The metabolism of Dexrabeprazole can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Pentobarbital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Voriconazole can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Primidone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of St. John's Wort can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Etravirine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The metabolism of Voxelotor can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The metabolism of Labetalol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The metabolism of Nebivolol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Thiopental can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Phenobarbital can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The metabolism of Vismodegib can be increased when combined with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The metabolism of Vismodegib can be increased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The metabolism of Dextromethorphan can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The metabolism of Meloxicam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00576</drugbank-id>
      <name>Sulfamethizole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfamethizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Oxandrolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Nilutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00891</drugbank-id>
      <name>Sulfapyridine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfapyridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01117</drugbank-id>
      <name>Atovaquone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Atovaquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Cyclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Ginkgo biloba.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01411</drugbank-id>
      <name>Pranlukast</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Pranlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Topiroxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03756</drugbank-id>
      <name>Doconexent</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Doconexent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06150</drugbank-id>
      <name>Sulfadimethoxine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfadimethoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06174</drugbank-id>
      <name>Noscapine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Noscapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sitaxentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Agomelatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08798</drugbank-id>
      <name>Sulfamoxole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Sulfamoxole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The metabolism of Glimepiride can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The metabolism of Desogestrel can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The metabolism of Bexarotene can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The metabolism of Hydromorphone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The metabolism of Treprostinil can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The metabolism of Acetohexamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Promazine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Nabumetone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The metabolism of Tenoxicam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The metabolism of Montelukast can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The metabolism of Celecoxib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Rofecoxib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The metabolism of Valdecoxib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The metabolism of Chlorpropamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The metabolism of Flurbiprofen can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The metabolism of Nateglinide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The metabolism of Etodolac can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The metabolism of Candesartan cilexetil can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The metabolism of Tolazamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The metabolism of Donepezil can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The metabolism of Ondansetron can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The metabolism of Salicylic acid can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Alosetron can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The metabolism of Formoterol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Methoxyflurane can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The metabolism of Tolterodine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The metabolism of Thalidomide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The metabolism of Glipizide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The metabolism of Diphenhydramine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The metabolism of Gliclazide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The metabolism of Thiamylal can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The metabolism of Halothane can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The metabolism of Moclobemide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The metabolism of Idarubicin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The metabolism of Gliquidone can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The metabolism of Arformoterol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The metabolism of Lumiracoxib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The metabolism of Glisoxepide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Flunitrazepam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The metabolism of Quazepam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04557</drugbank-id>
      <name>Arachidonic Acid</name>
      <description>The metabolism of Arachidonic Acid can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The metabolism of Coumarin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The metabolism of Ximelagatran can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Ospemifene can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The metabolism of Trabectedin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The metabolism of Brivaracetam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The metabolism of Tapentadol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The metabolism of Prasugrel can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The metabolism of Dapagliflozin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Indisulam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06652</drugbank-id>
      <name>Vicriviroc</name>
      <description>The metabolism of Vicriviroc can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The metabolism of Lornoxicam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The metabolism of Zaltoprofen can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06803</drugbank-id>
      <name>Niclosamide</name>
      <description>The metabolism of Niclosamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The metabolism of Tranilast can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The metabolism of Cabozantinib can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The metabolism of Glibornuride can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Cannabidiol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>The metabolism of Lesinurad can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The metabolism of Asunaprevir can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The metabolism of Rupatadine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The metabolism of Carbutamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The metabolism of Metahexamide can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The metabolism of Candesartan can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13941</drugbank-id>
      <name>Piperaquine</name>
      <description>The metabolism of Piperaquine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Nabiximols can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Benzbromarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Felodipine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The metabolism of Mefenamic acid can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Tienilic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04856</drugbank-id>
      <name>Dexloxiglumide</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Dexloxiglumide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Aprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Eletriptan can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The metabolism of Alprazolam can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Bupropion can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The metabolism of Dicoumarol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Quinidine can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The metabolism of Siponimod can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The metabolism of Fluindione can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Vismodegib can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Vismodegib can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Vismodegib can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Vismodegib can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Vismodegib can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Vismodegib can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Vismodegib can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Vismodegib may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tenofovir disoproxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00360</drugbank-id>
      <name>Sapropterin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sapropterin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Amodiaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Clofazimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02010</drugbank-id>
      <name>Staurosporine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Staurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02587</drugbank-id>
      <name>Colforsin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Colforsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Taurocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cholesterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04851</drugbank-id>
      <name>Biricodar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Biricodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04877</drugbank-id>
      <name>Voacamine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Voacamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06240</drugbank-id>
      <name>Tariquidar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tariquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06448</drugbank-id>
      <name>Lonafarnib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lonafarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06733</drugbank-id>
      <name>Bafilomycin A1</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bafilomycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06734</drugbank-id>
      <name>Bafilomycin B1</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bafilomycin B1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fidaxomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ledipasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Paritaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Chloroform.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11430</drugbank-id>
      <name>Monensin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Monensin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11544</drugbank-id>
      <name>Salinomycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Salinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Velpatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tezacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Valspodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Abemaciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Voxilaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Letermovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12799</drugbank-id>
      <name>Laniquidar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Laniquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lusutrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Pibrentasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Glecaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14056</drugbank-id>
      <name>Nigericin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nigericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Valinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14061</drugbank-id>
      <name>Hycanthone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Hycanthone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14062</drugbank-id>
      <name>Concanamycin A</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Concanamycin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14069</drugbank-id>
      <name>ONT-093</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with ONT-093.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14070</drugbank-id>
      <name>HM-30181</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with HM-30181.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14071</drugbank-id>
      <name>Desmethylsertraline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Desmethylsertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14072</drugbank-id>
      <name>Reversin 121</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Reversin 121.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The serum concentration of Nisoldipine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The serum concentration of Meperidine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The serum concentration of Buspirone can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The serum concentration of Astemizole can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The serum concentration of Alfentanil can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The serum concentration of Fentanyl can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The serum concentration of Conivaptan can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Tipranavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The serum concentration of Darunavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The serum concentration of Lopinavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Dronedarone can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The serum concentration of Lomitapide can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The serum concentration of Rilpivirine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The serum concentration of Eliglustat can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Vismodegib can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14033</drugbank-id>
      <name>Acetyl sulfisoxazole</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Acetyl sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The metabolism of Vismodegib can be decreased when combined with Oritavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ascorbic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Raloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Alitretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Mannitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Clomifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Levetiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Neostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Testosterone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Stanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Sphingosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rhodamine 6G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Estriol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Cobimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Silodosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Prucalopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The serum concentration of Tenofovir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Indinavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Terfenadine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The serum concentration of Vardenafil can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Tolvaptan can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The serum concentration of Ticagrelor can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Naloxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Cenobamate can be decreased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be increased when it is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The serum concentration of Vismodegib can be decreased when it is combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Vismodegib can be decreased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Vismodegib can be decreased when it is combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Vismodegib may decrease the excretion rate of Folic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Vismodegib may decrease the excretion rate of Pravastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>Vismodegib may decrease the excretion rate of Cladribine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Vismodegib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Vismodegib may decrease the excretion rate of Allopurinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>Vismodegib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Vismodegib may decrease the excretion rate of Teniposide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>Vismodegib may decrease the excretion rate of Zidovudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>Vismodegib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>Vismodegib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Vismodegib may decrease the excretion rate of Methotrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Vismodegib may decrease the excretion rate of Clofarabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>Vismodegib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Vismodegib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Vismodegib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>Vismodegib may decrease the excretion rate of Lamivudine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>Vismodegib may decrease the excretion rate of Riluzole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>Vismodegib may decrease the excretion rate of Irinotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Vismodegib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Vismodegib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>Vismodegib may decrease the excretion rate of Topotecan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>Vismodegib may decrease the excretion rate of Tegaserod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Vismodegib may decrease the excretion rate of Leflunomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Vismodegib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>Vismodegib may decrease the excretion rate of Alvocidib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>Vismodegib may decrease the excretion rate of Camptothecin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Vismodegib may decrease the excretion rate of Simeprevir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>Vismodegib may decrease the excretion rate of Pazopanib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Vismodegib may decrease the excretion rate of Apixaban which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>Vismodegib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Vismodegib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>Vismodegib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Vismodegib may decrease the excretion rate of Riociguat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>Vismodegib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>Vismodegib may decrease the excretion rate of Palbociclib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Vismodegib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>Vismodegib may decrease the excretion rate of Fimasartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>Vismodegib may decrease the excretion rate of Ombitasvir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>Vismodegib may decrease the excretion rate of Osimertinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>Vismodegib may decrease the excretion rate of Moxidectin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>Vismodegib may decrease the excretion rate of Talazoparib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Vismodegib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Vismodegib may decrease the excretion rate of Revefenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Vismodegib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Vismodegib may decrease the excretion rate of Duvelisib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>Vismodegib may decrease the excretion rate of Dacomitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>Vismodegib may decrease the excretion rate of Glasdegib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>Vismodegib may decrease the excretion rate of Brigatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>Vismodegib may decrease the excretion rate of Copanlisib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>Vismodegib may decrease the excretion rate of Larotrectinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>Vismodegib may decrease the excretion rate of Darolutamide which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.22</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.73e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>vismodegib</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>421.297</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>420.010218428</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H14Cl2N2O3S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BPQMGSKTAYIVFO-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>76.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>107.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>39.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>10.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>0.1 Œºg/mL and is pH dependent </value>
      <source>FDA label </source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.7 </value>
      <source>FDA label </source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>3.8</value>
      <source>FDA label </source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22125</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>66903</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>24776445</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427109</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D09992</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>23337846</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50249522</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA166048558</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>VIS</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Vismodegib</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL473417</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/erivedge-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/vismodegib.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004659</id>
      <name>Smoothened homolog</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7370</ref-id>
            <pubmed-id>23662017</pubmed-id>
            <citation>Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q99835" source="Swiss-Prot">
        <name>Smoothened homolog</name>
        <general-function>Wnt-protein binding</general-function>
        <specific-function>G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.</specific-function>
        <gene-name>SMO</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>234-254
263-283
315-335
359-379
403-423
452-472
525-545</transmembrane-regions>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi/>
        <molecular-weight>86395.95</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>239</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q99835</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SMO_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Protein Gx</synonym>
          <synonym>SMO</synonym>
          <synonym>SMOH</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021716|Smoothened homolog
MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARRSAAVTGPPPP
LSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQEEAHGKLVLWSGLRNAPRCWA
VIQPLLCAVYMPKCENDRVELPSRTLCQATRGPCAIVERERGWPDFLRCTPDRFPEGCTN
EVQNIKFNSSGQCEVPLVRTDNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAV
TGLCTLFTLATFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGT
MRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTYQPLSGKTSYF
HLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYRAGFVLAPIGLVLIVGGYFLI
RGVMTLFSIKSNHPGLLSEKAASKINETMLRLGIFGFLAFGFVLITFSCHFYDFFNQAEW
ERSFRDYVLCQANVTIGLPTKQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKA
TLLIWRRTWCRLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPV
AGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEEQANLWLVEAE
ISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPSTIPRLPQLPRQKCLVAAGAWG
AGDSCRQGAWTLVSNPFCPEPSPPQDPFLPSAPAPVAWAHGRRQGLGPIHSRTNLMDTEL
MDADSDF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021717|Smoothened homolog (SMO)
ATGGCCGCTGCCCGCCCAGCGCGGGGGCCGGAGCTCCCGCTCCTGGGGCTGCTGCTGCTG
CTGCTGCTGGGGGACCCGGGCCGGGGGGCGGCCTCGAGCGGGAACGCGACCGGGCCTGGG
CCTCGGAGCGCGGGCGGGAGCGCGAGGAGGAGCGCGGCGGTGACTGGCCCTCCGCCGCCG
CTGAGCCACTGCGGCCGGGCTGCCCCCTGCGAGCCGCTGCGCTACAACGTGTGCCTGGGC
TCGGTGCTGCCCTACGGGGCCACCTCCACACTGCTGGCCGGAGACTCGGACTCCCAGGAG
GAAGCGCACGGCAAGCTCGTGCTCTGGTCGGGCCTCCGGAATGCCCCCCGCTGCTGGGCA
GTGATCCAGCCCCTGCTGTGTGCCGTATACATGCCCAAGTGTGAGAATGACCGGGTGGAG
CTGCCCAGCCGTACCCTCTGCCAGGCCACCCGAGGCCCCTGTGCCATCGTGGAGAGGGAG
CGGGGCTGGCCTGACTTCCTGCGCTGCACTCCTGACCGCTTCCCTGAAGGCTGCACGAAT
GAGGTGCAGAACATCAAGTTCAACAGTTCAGGCCAGTGCGAAGTGCCCTTGGTTCGGACA
GACAACCCCAAGAGCTGGTACGAGGACGTGGAGGGCTGCGGCATCCAGTGCCAGAACCCG
CTCTTCACAGAGGCTGAGCACCAGGACATGCACAGCTACATCGCGGCCTTCGGGGCCGTC
ACGGGCCTCTGCACGCTCTTCACCCTGGCCACATTCGTGGCTGACTGGCGGAACTCGAAT
CGCTACCCTGCTGTTATTCTCTTCTACGTCAATGCGTGCTTCTTTGTGGGCAGCATTGGC
TGGCTGGCCCAGTTCATGGATGGTGCCCGCCGAGAGATCGTCTGCCGTGCAGATGGCACC
ATGAGGCTTGGGGAGCCCACCTCCAATGAGACTCTGTCCTGCGTCATCATCTTTGTCATC
GTGTACTACGCCCTGATGGCTGGTGTGGTTTGGTTTGTGGTCCTCACCTATGCCTGGCAC
ACTTCCTTCAAAGCCCTGGGCACCACCTACCAGCCTCTCTCGGGCAAGACCTCCTACTTC
CACCTGCTCACCTGGTCACTCCCCTTTGTCCTCACTGTGGCAATCCTTGCTGTGGCGCAG
GTGGATGGGGACTCTGTGAGTGGGATTTGTTTTGTGGGCTACAAGAACTACCGATACCGT
GCGGGCTTCGTGCTGGCCCCAATCGGCCTGGTGCTCATCGTGGGAGGCTACTTCCTCATC
CGAGGAGTCATGACTCTGTTCTCCATCAAGAGCAACCACCCCGGGCTGCTGAGTGAGAAG
GCTGCCAGCAAGATCAACGAGACCATGCTGCGCCTGGGCATTTTTGGCTTCCTGGCCTTT
GGCTTTGTGCTCATTACCTTCAGCTGCCACTTCTACGACTTCTTCAACCAGGCTGAGTGG
GAGCGCAGCTTCCGGGACTATGTGCTATGTCAGGCCAATGTGACCATCGGGCTGCCCACC
AAGCAGCCCATCCCTGACTGTGAGATCAAGAATCGCCCGAGCCTTCTGGTGGAGAAGATC
AACCTGTTTGCCATGTTTGGAACTGGCATCGCCATGAGCACCTGGGTCTGGACCAAGGCC
ACGCTGCTCATCTGGAGGCGTACCTGGTGCAGGTTGACTGGGCAGAGTGACGATGAGCCA
AAGCGGATCAAGAAGAGCAAGATGATTGCCAAGGCCTTCTCTAAGCGGCACGAGCTCCTG
CAGAACCCAGGCCAGGAGCTGTCCTTCAGCATGCACACTGTGTCCCACGACGGGCCCGTG
GCGGGCTTGGCCTTTGACCTCAATGAGCCCTCAGCTGATGTCTCCTCTGCCTGGGCCCAG
CATGTCACCAAGATGGTGGCTCGGAGAGGAGCCATACTGCCCCAGGATATTTCTGTCACC
CCTGTGGCAACTCCAGTGCCCCCAGAGGAACAAGCCAACCTGTGGCTGGTTGAGGCAGAG
ATCTCCCCAGAGCTGCAGAAGCGCCTGGGCCGGAAGAAGAAGAGGAGGAAGAGGAAGAAG
GAGGTGTGCCCGCTGGCGCCGCCCCCTGAGCTTCACCCCCCTGCCCCTGCCCCCAGTACC
ATTCCTCGACTGCCTCAGCTGCCCCGGCAGAAATGCCTGGTGGCTGCAGGTGCCTGGGGA
GCTGGGGACTCTTGCCGACAGGGAGCGTGGACCCTGGTCTCCAACCCATTCTGCCCAGAG
CCCAGTCCCCCTCAGGATCCATTTCTGCCCAGTGCACCGGCCCCCGTGGCATGGGCTCAT
GGCCGCCGACAGGGCCTGGGGCCTATTCACTCCCGCACCAACCTGATGGACACAGAACTC
ATGGATGCAGACTCGGACTTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01392</identifier>
            <name>Fz</name>
          </pfam>
          <pfam>
            <identifier>PF01534</identifier>
            <name>Frizzled</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>ciliary membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ciliary tip</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>patched binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Wnt-protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anterior/posterior pattern specification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>astrocyte activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>atrial septum morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell fate specification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cholesterol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>central nervous system neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellar cortex morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dentate gyrus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of cell density by contact stimulus involved in contact inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>determination of left/right asymmetry in lateral mesoderm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dorsal/ventral neural tube patterning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial-mesenchymal cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>forebrain morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hair follicle morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart looping</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>homeostasis of number of cells within a tissue</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>left/right axis specification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mesenchymal to epithelial transition involved in metanephric renal vesicle formation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>midgut development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of hair follicle development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neural crest cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>odontogenesis of dentin-containing tooth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pancreas morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of branching involved in ureteric bud morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of hh target transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mesenchymal cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smoothened signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein stabilization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of stem cell population maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle fiber development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smoothened signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smoothened signaling pathway involved in ventral spinal cord patterning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>somite development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thalamus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>type B pancreatic cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasculogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventral midline determination</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0002793</id>
      <name>Cytochrome P450 2C9</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7370</ref-id>
            <pubmed-id>23662017</pubmed-id>
            <citation>Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F1886</ref-id>
            <title>Vismodegib FDA Label</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/886/original/203388lbl.pdf?1539710613</url>
          </attachment>
        </attachments>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P11712" source="Swiss-Prot">
        <name>Cytochrome P450 2C9</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.</specific-function>
        <gene-name>CYP2C9</gene-name>
        <locus>10q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.99</theoretical-pi>
        <molecular-weight>55627.365</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2623</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY341248</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11712</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2C10</synonym>
          <synonym>CYPIIC9</synonym>
          <synonym>Cytochrome P-450MP</synonym>
          <synonym>Cytochrome P450 MP-4</synonym>
          <synonym>Cytochrome P450 MP-8</synonym>
          <synonym>Cytochrome P450 PB-1</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005471|Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)
ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT
GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG
TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT
CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG
AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT
CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT
GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG
ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA
GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC
CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC
ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG
AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG
GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT
CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG
CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urea metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7370</ref-id>
            <pubmed-id>23662017</pubmed-id>
            <citation>Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38787</ref-id>
            <pubmed-id>23319845</pubmed-id>
            <citation>Fellner C: Vismodegib (erivedge) for advanced Basal cell carcinoma. P T. 2012 Dec;37(12):670-82.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F1492</ref-id>
            <title>Vismodegib</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/492/original/FDA_label__vismodegib.pdf?1536960870</url>
          </attachment>
        </attachments>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="8">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
    <carrier position="9">
      <id>BE0000925</id>
      <name>Alpha-1-acid glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02763" source="Swiss-Prot">
        <name>Alpha-1-acid glycoprotein 1</name>
        <general-function/>
        <specific-function>Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.</specific-function>
        <gene-name>ORM1</gene-name>
        <locus>9q31-q32</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>4.66</theoretical-pi>
        <molecular-weight>23511.38</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8498</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ORM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02544</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>757907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02763</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A1AG1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AGP 1</synonym>
          <synonym>AGP1</synonym>
          <synonym>OMD 1</synonym>
          <synonym>Orosomucoid-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001842|Alpha-1-acid glycoprotein 1
MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAFRNEEYNKSVQ
EIQATFFYFTPNKTEDTIFLREYQTRQDQCIYNTTYLNVQRENGTISRYVGGQEHFAHLL
ILRDTKTYMLAFDVNDEKNWGLSVYADKPETTKEQLGEFYEALDCLRIPKSDVVYTDWKK
DKCEPLEKQHEKERKQEEGES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010649|Alpha-1-acid glycoprotein 1 (ORM1)
ATGGCGCTGTCCTGGGTTCTTACAGTCCTGAGCCTCCTACCTCTGCTGGAAGCCCAGATC
CCATTGTGTGCCAACCTAGTACCGGTGCCCATCACCAACGCCACCCTGGACCGGATCACT
GGCAAGTGGTTTTATATCGCATCGGCCTTTCGAAACGAGGAGTACAATAAGTCGGTTCAG
GAGATCCAAGCAACCTTCTTTTACTTCACCCCCAACAAGACAGAGGACACGATCTTTCTC
AGAGAGTACCAGACCCGACAGGACCAGTGCATCTATAACACCACCTACCTGAATGTCCAG
CGGGAAAATGGGACCATCTCCAGATACGTGGGAGGCCAAGAGCATTTCGCTCACTTGCTG
ATCCTCAGGGACACCAAGACCTACATGCTTGCTTTTGACGTGAACGATGAGAAGAACTGG
GGGCTGTCTGTCTATGCTGACAAGCCAGAGACGACCAAGGAGCAACTGGGAGAGTTCTAC
GAAGCTCTCGACTGCTTGCGCATTCCCAAGTCAGATGTCGTGTACACCGATTGGAAAAAG
GATAAGTGTGAGCCACTGGAGAAGCAGCACGAGAAGGAGAGGAAACAGGAGGAGGGGGAA
TCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00061</identifier>
            <name>Lipocalin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute-phase response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of immune system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters>
    <transporter position="4">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7370</ref-id>
            <pubmed-id>23662017</pubmed-id>
            <citation>Sandhiya S, Melvin G, Kumar SS, Dkhar SA: The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7. doi: 10.4103/0976-500X.107628.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>